A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Tablet in Obese Subjects
Latest Information Update: 18 Jun 2025
At a glance
- Drugs HRS 9531 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Fujian Shengdi Pharmaceutical
Most Recent Events
- 12 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 24 Apr 2025 Status changed from not yet recruiting to recruiting.
- 03 Mar 2025 New trial record